Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2010 | Original Paper

Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer

Authors: Wenjun Cheng, Yi Jiang, Cuixia Liu, Ouxi Shen, Weiwei Tang, Xinru Wang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2010

Abstract

Purpose

The purpose of this study was to determine the relationship between hypomethylation of HOXA10 gene’s promoter and high expression in malignant ovarian tissues, and to confirm the level of hypomethylation in ovarian cell lines.

Experimental design

We performed the methylation status of 29 samples from ovarian carcinomas and 16 from normal tissues by methylation-specific polymerase chain reaction (MSP). Then, we evaluated the expression of mRNA and protein of HOXA10 in all samples to work out the relationship between the methylation status of HOXA10 and its expression in transcriptional and translational levels. We then confirmed our present study usingSKOV3 and HEY ovarian cancer cell lines treated with the demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) to detect whether the expression of HoxA10 in the two cell lines was altered.

Results

Increased expression of HOXA10 was detected in almost all ovarian carcinomas (p < 0.05). Promoter hypomethylation was found in (17 of 29) 58.62% ovarian cancers and (4 of 16) 25% normal ovaries (p < 0.05). The HOXA10 expression is higher when the status of HOXA10 gene promoter is hypomethylated than in methylated tissues (p < 0.05). After 5-aza-dC treatment, the expression level of HOXA10 mRNA transcript was increased in the two cell lines.

Conclusion

Our results indicate that promoter hypomethylation is an important mechanism for high expression of HOXA10 in human ovarian cancer and may be a potential prognostic factor in ovarian cancer.

Balch C, Huang TH, Brown R, Nephew KP (2004) The epigenitics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191:1552–1572CrossRefPubMed

Cheng W, Liu J, Yoshida H, Rosen D, Naora H (2005) Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in thec reproductive tract. Nat Med 11:531–537CrossRefPubMed

Daffary GS, Troy PJ, Bagot CN, Young SL, Taylor HS (2002) Direct regulation of β3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol 16(3):571–579CrossRef

Das PM, Singal R (2004) DNA methylation and cancer. J Clin Oncol 22:4632–4642CrossRefPubMed

Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, Campan M, Weisenberger DJ, Long T, Youn B, Fiala ES, Laird PW (2006) Quantitative analysis of associations between DNA hypermethylations, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25:2636–2645CrossRefPubMed

Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153CrossRefPubMed

Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89–92CrossRefPubMed

Fraga MF, Agrelo R, Esteller M (2007) Cross-talk between aging and cancer: the epigenetic language. Ann NY Acad Sci 1100:60–74CrossRefPubMed

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826CrossRefPubMed

Issa JA (2000) CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249:101–118PubMed

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428CrossRefPubMed

Kelly M, Daftary G, Taylor HS (2006) An autoregulatory element maintains HOXA10 expression in endometrial epithelial cells. Am J Obstet Gynecol 194:1100–1109CrossRefPubMed

Lechner JF, Fugaro JM, Wong Y, Pass HI, Harris CC, Belinsky SA (2001) Perspective: cell differentiation theory may advance early detection of and therapy for lung cancer. Radiat Res 155:235–238CrossRefPubMed

Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK (2003) Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 63:5879–5888PubMed

Momparler RL (2003) Cancer epigenetics. Oncogene 22:6479–6483CrossRefPubMed

Ones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293:1068–1070CrossRef

Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA (2004) Reversal of the hypomethylation status of urokinase(uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 279:31735–31744CrossRefPubMed

Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, Mutirangura A (2008) LINE-1 hypomethylation level as potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18:711–717CrossRefPubMed

Shen JC, Richeout WM 3rd, Jones PA (1992) High frequency mutagenesis by a DNA methyltransferase. Cell 71:1073–1080CrossRefPubMed

Shi H, Wang MX, Caldwell CW (2007) CpG islands: their potential as biomarker for cancer. Expert Rev Mol Diagn 7(5):519–531CrossRefPubMed

Swanton C, Nicke B, Downward J (2004) RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy? Lancet Oncol 5:653–654CrossRefPubMed

Szyf M, Pakneshan P, Rabbani SA (2004) DNA demethylation and cancer: therapeutic implications. Cancer Lett 211:133–143CrossRefPubMed

Vider BZ, Zimber A, Hirsch D, Estlein D, Chastre E, Prevot S, Gespach C, Yaniv A, Gazit A (1997) Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. Biochem Biophys Res Commun 232(3):742–748CrossRefPubMed

Vider BZ, Zimber A, Chastre E, Gespach C, Halperin M, Mashiah P, Yaniv A, Gazit A (2000) Deregulated expression of homeobox-cotaining genes, HOXB6, B8, C8, C9, and Cdx-1, in human colon cancer cell lines. Biochem Biophys Res Commun 272:513–518CrossRefPubMed

Wang C, Zhang B, Shen H (2004) Expression of HOXA9 mRNA and its clinical significance in primary hepatocarcinoma. China J Mod Med 1:14

Title: Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer
Authors: Wenjun Cheng
Yi Jiang
Cuixia Liu
Ouxi Shen
Weiwei Tang
Xinru Wang
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0772-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2010

Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

Epigenetic silencing of WIF-1 in hepatocellular carcinomas

(−)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells

Clinical significance of pAKT and CD44v6 overexpression with breast cancer

Detection and identification of potential biomarkers of breast cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials